天境生物 IMAB 深 沪
已收盘 10-29 16:00:00 美东时间
4.63
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.63
- 总市值 5.32亿
- 52周最高 6.79
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.595
- 委 比 0.00%
- 总股本 1.15亿
- 历史最高 85.40
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.595
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study
BRIEF-Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study June 14 (Reuters) - Celldex Therapeutics Inc CLDX.O : CELLDEX PRESENTS LONG-TERM BARZOLVOLIMAB RESULTS DEMONSTRATING SUSTAINED OFF-TREATMENT IMPROVEMENT IN ANGIOEDEMA IN PATIENTS WITH CSU AT THE EUROPE
06-14 22:26
BRIEF-Regeneron Provides Update On Phase 3 Trial Of Fianlimab (Lag-3 Inhibitor) Combination In First-Line Unresectable Or Metastatic Melanoma
BRIEF-Regeneron Provides Update On Phase 3 Trial Of Fianlimab (Lag-3 Inhibitor) Combination In First-Line Unresectable Or Metastatic Melanoma May 16 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PROVIDES UPDATE ON PHASE 3 TRIAL OF FIANLIMAB (LAG-3 INHIBITOR) COMBINATION IN FIRST-LINE
05-16 08:24
8.5亿美元！渤健与天境生物达成协议，获菲泽妥单抗大中华区独家权益
（来源：求实药社） 4月20日，天境生物（TJ Biopharma）与渤健生物（Biogen）共同宣布，双方已就菲泽妥单抗达成一项最终协议。渤健将获得该药物在大...
04-21 12:04
渤健斥资8.5亿美元从天境生物购得免疫疾病药物大中华区权益
渤健公司已与天境生物达成最终协议，收购后者持有的菲泽妥单抗在大中华区的独家权益。通过此次交易，渤健获得了该药物全球范围内的独家开发和商业化权利。 根据协...
04-20 21:36
药物受理最新动态：天境生物药业（杭州）股份有限公司普那利单抗注射液新药申请获受理
国家药品监督管理局药品审评中心数据显示，2026年4月2日，天境生物药业（杭州）股份有限公司的普那利单抗注射液申请已获受理，受理号为CXSL2600373。 ...
04-02 14:15
BRIEF-Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
BRIEF-Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting March 18 (Reuters) - InflaRx NV IF0G.F : INFLARX ANNOUNCES LATE-BREAKER ORAL PRESENTATION ON VILOBELIMAB PHASE 3 RESULTS IN PYODERMA GA
03-18 19:57
BRIEF-Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
BRIEF-Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab March 5 (Reuters) - Cytodyn Inc CYDY.PK : CYTODYN CLOSES $17.5 MILLION FINANCING TO FUND CONTINUED DEVELOPMENT OF LERONLIMAB Source text: ID:nGNX91D0Rt Further company coverage: CYDY.PK (( Reuters.Briefs@thomson
03-05 21:31
BRIEF-Kyowa Kirin Announces Discontinuation Of Rocatinlimab Clinical Trials
BRIEF-Kyowa Kirin Announces Discontinuation Of Rocatinlimab Clinical Trials March 3 (Reuters) - Kyowa Kirin Co Ltd 4151.T : KYOWA KIRIN ANNOUNCES DISCONTINUATION OF ROCATINLIMAB CLINICAL TRIALS Source text: ID:nGNX1Pcm15 Further company coverage: 4151.T (( Reuters.Briefs@thomsonreuters.com ;))
03-03 21:07
